APA (7th ed.) Citation

J, K., KW, P., JK, H., D, H., HM, Y., S, P., . . . HS, K. (2025). Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): An open-label, multicentre, randomised clinical trial. Lancet (London, England), 406(10516), 2244. https://doi.org/10.1016/S0140-6736(25)01571-5

Chicago Style (17th ed.) Citation

J, Kang, et al. "Dual Antiplatelet Therapy After Percutaneous Coronary Intervention According to Bleeding Risk (HOST-BR): An Open-label, Multicentre, Randomised Clinical Trial." Lancet (London, England) 406, no. 10516 (2025): 2244. https://doi.org/10.1016/S0140-6736(25)01571-5.

MLA (9th ed.) Citation

J, Kang, et al. "Dual Antiplatelet Therapy After Percutaneous Coronary Intervention According to Bleeding Risk (HOST-BR): An Open-label, Multicentre, Randomised Clinical Trial." Lancet (London, England), vol. 406, no. 10516, 2025, p. 2244, https://doi.org/10.1016/S0140-6736(25)01571-5.